According to Amphastar Pharmaceuticals's latest financial reports the company's current revenue (TTM) is $0.64 B. In 2022 the company made a revenue of $0.49 B an increase over the years 2021 revenue that were of $0.43 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.64 B | 29.14% |
2022 | $0.49 B | 13.98% |
2021 | $0.43 B | 25.13% |
2020 | $0.34 B | 8.53% |
2019 | $0.32 B | 9.4% |
2018 | $0.29 B | 22.69% |
2017 | $0.24 B | -5.87% |
2016 | $0.25 B | 1.45% |
2015 | $0.25 B | 19.51% |
2014 | $0.21 B | -8.37% |
2013 | $0.22 B |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Tonix Pharmaceuticals TNXP | $7.76 M | -98.79% | ๐บ๐ธ USA |
SCYNEXIS SCYX | $0.14 B | -78.25% | ๐บ๐ธ USA |
Marinus Pharmaceuticals MRNS | $30.98 M | -95.19% | ๐บ๐ธ USA |
Agile Therapeutics
AGRX | $19.59 M | -96.96% | ๐บ๐ธ USA |